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background: LDL particle concentrations are associated with cardiovascular disease. Subclasses of lipoprotein particles, defined by size, may 
have different atherogenic properties. We evaluated the effect of evolocumab (formerly AMG 145) on LDL, VLDL, and HDL particles (LDL-P, VLDL-P, 
HDL-P), size, and subclass cholesterol content in hypercholesterolemic and HeFH subjects.
methods: Exploratory biomarker samples from a phase 1b study were used. Hypercholesterolemic subjects on low to moderate dose statins 
received evolocumab ranging from 14 mg (QW) to 420 mg (Q4W) or placebo. Subjects on high dose statins and HeFH subjects received 140 mg 
evolocumab (Q2W) or placebo. In baseline and post-dose samples, LDL-P, VLDL-P, and HDL-P and size were determined by NMR. Cholesterol of 
lipoprotein subclasses was measured by VAP.
results: Results from subjects receiving 140 mg evolocumab Q2W or placebo are summarized below:
Day 43 LS Geometric Mean Ratio to Baseline (95% CI)
Hypercholesterolemic Subjects HeFH Subjects
Placebo (n=12)
140 mg Evolocumab (Q2W) + Low-Moderate 
Dose Statin (n=6)
140 mg Evolocumab (Q2W) + High 
Dose Statin (n=9)
Placebo 
(n=2)
140 mg Evolocumab + Statin (n=4)
NMR Result LDL-P 0.96 (0.81,1.13) 0.28c (0.22,0.36) 0.34c (0.28,0.42) 0.99 (0.64,1.54) 0.57a (0.42,0.77)
Large LDL-P 1.01 (0.72,1.41) 0.40b (0.25,0.64) 0.64 (0.43,0.95) 1.01 (0.37,2.74) 0.33 (0.16,0.68)
Small LDL-P 0.87 (0.64,1.18) 0.13c (0.08,0.20) 0.20c (0.14,0.29) 0.85 (0.38,1.89) 0.63 (0.36,1.11)
LDL Size 1.01 (0.99,1.03) 1.04a (1.01,1.06) 1.04a (1.02,1.06) 1.00 (0.96,1.04) 0.97 (0.95,1.00)
VLDL-P 0.91 (0.73,1.15) 0.56a (0.40,0.77) 0.52b (0.40,0.69) 1.55 (0.72,3.32) 0.26c (0.15,0.45)
VLDL Size 0.97 (0.91,1.03) 1.14b (1.04,1.25) 1.13b (1.05,1.23) 0.95 (0.76,1.19) 1.40b (1.19,1.64)
HDL-P 1.00 (0.95,1.05) 1.05 (0.97,1.12) 1.05 (0.99,1.12) 1.10 (0.95,1.27) 1.22 (1.10,1.36)
HDL Size 1.01 (0.99,1.02) 1.01 (0.99,1.03) 1.04c (1.02,1.05) 1.00 (0.97,1.03) 1.02 (1.00,1.04)
VAP Result LDL-C 0.97 (0.83,1.15) 0.26c (0.20,0.33) 0.34c (0.28,0.41) 0.96 (0.62,1.48) 0.39c (0.28,0.53)
LDL1 (Large) 1.02 (0.71,1.46) 0.23c (0.12,0.45) 0.15c (0.10,0.24) 1.02 (0.48,2.18) 0.38a (0.22,0.65)
LDL2 (Large) 0.83 (0.52,1.34) 0.30 (0.07,1.34) 0.06c (0.03,0.13) 0.84 (0.29,2.48) 0.17a (0.08,0.36)
LDL3 (Small) 0.91 (0.71,1.18) 0.16c (0.11,0.23) 0.16c (0.12,0.23) 0.86 (0.46,1.63) 0.29b (0.18,0.45)
LDL4 (Small) 0.97 (0.75,1.27) 0.58a (0.40,0.84) 0.49c (0.36,0.68) 1.25 (0.53,2.92) 0.71 (0.39,1.30)
VLDL-C 0.96 (0.86,1.07) 0.73b (0.63,0.85) 0.71c (0.63,0.81) 1.18 (0.81,1.70) 0.84 (0.65,1.10)
HDL-C 0.96 (0.89,1.04) 1.04 (0.93,1.15) 1.13b (1.03,1.23) 1.00 (0.85,1.17) 1.16 (1.03,1.29)
p - value associated with each dose vs. corresponding placebo, a: p ≤ 0.05; b: p ≤ 0.01 and c: p ≤ 0.001
Overall, evolocumab lowered total, small, and large LDL-P. In most cohorts, small LDL-P was reduced more than large LDL-P and mean LDL size 
increased. LDL-C lowering correlated better to reductions in small LDL-P compared to large LDL-P. Also, LDL-C was reduced across all subclasses. In 
general, LDL4 was reduced the least. Reductions in VLDL-P and VLDL-C and increases in HDL-P and HDL-C were also observed in some cohorts.
conclusion: In this study, evolocumab treatment lowered VLDL-P, VLDL-C, LDL-C, and LDL-P, with a significant effect on small LDL-P. HDL-P and 
HDL-C also trended up.
